Does the media prefer ALKS or ABEO?

In the previous week, Abeona Therapeutics had 5 more articles in the media than Alkermes. MarketBeat recorded 15 mentions for Abeona Therapeutics and 10 mentions for Alkermes. Alkermes' average media sentiment score of 0.80 beat Abeona Therapeutics' score of 0.33 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abeona Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ALKS or MEDP?

Medpace has higher revenue and earnings than Alkermes. Medpace is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.48B 5.86 $241.66M $0.90 57.63 Medpace $2.53B 5.98 $451.12M $15.91 33.32

Is ALKS or MEDP more profitable?

Medpace has a net margin of 17.19% compared to Alkermes' net margin of 9.78%. Medpace's return on equity of 120.89% beat Alkermes' return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 9.78% 9.26% 5.66% Medpace 17.19% 120.89% 24.79%

Does the media refer more to ALKS or MEDP?

In the previous week, Medpace had 4 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for Medpace and 10 mentions for Alkermes. Alkermes' average media sentiment score of 0.80 beat Medpace's score of 0.77 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, OMCL or ALKS?

Alkermes has higher revenue and earnings than Omnicell. Alkermes is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.79 $2.05M $0.44 106.09 Alkermes $1.48B 5.86 $241.66M $0.90 57.63

Is OMCL or ALKS more profitable?

Alkermes has a net margin of 9.78% compared to Omnicell's net margin of 1.67%. Alkermes' return on equity of 9.26% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 1.67% 4.00% 2.46% Alkermes 9.78% 9.26% 5.66%

Does the media favor OMCL or ALKS?

In the previous week, Alkermes had 2 more articles in the media than Omnicell. MarketBeat recorded 10 mentions for Alkermes and 8 mentions for Omnicell. Alkermes' average media sentiment score of 0.80 beat Omnicell's score of 0.58 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALKS or AMN?

In the previous week, AMN Healthcare Services had 9 more articles in the media than Alkermes. MarketBeat recorded 19 mentions for AMN Healthcare Services and 10 mentions for Alkermes. Alkermes' average media sentiment score of 0.80 beat AMN Healthcare Services' score of 0.38 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has higher earnings & valuation, BIIB or ALKS?

Biogen has higher revenue and earnings than Alkermes. Biogen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.12 $1.29B $9.32 22.43 Alkermes $1.48B 5.86 $241.66M $0.90 57.63

Is BIIB or ALKS more profitable?

Biogen has a net margin of 13.81% compared to Alkermes' net margin of 9.78%. Biogen's return on equity of 12.83% beat Alkermes' return on equity. Company Net Margins Return on Equity Return on Assets Biogen 13.81% 12.83% 8.01% Alkermes 9.78% 9.26% 5.66%

Does the media prefer BIIB or ALKS?

In the previous week, Biogen had 23 more articles in the media than Alkermes. MarketBeat recorded 33 mentions for Biogen and 10 mentions for Alkermes. Biogen's average media sentiment score of 0.93 beat Alkermes' score of 0.80 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 18 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alkermes (ALKS) Competitors

$51.87 -0.07 (-0.13%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$51.86 -0.01 (-0.02%)

As of 04:01 AM Eastern

Compare

ALKS vs. ABEO, MEDP, OMCL, AMN, and BIIB

Should you buy Alkermes stock or one of its competitors? MarketBeat compares Alkermes with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), and Biogen (BIIB). These companies are all part of the "medical" sector.

How does Alkermes compare to Abeona Therapeutics?

Alkermes (NASDAQ:ALKS) and Abeona Therapeutics (NASDAQ:ABEO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Alkermes currently has a consensus target price of $51.25, suggesting a potential downside of 1.20%. Abeona Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 171.04%. Given Abeona Therapeutics' higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Abeona Therapeutics	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Alkermes has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market.

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.86	$241.66M	$0.90	57.63
Abeona Therapeutics	$5.82M	68.64	$71.18M	$0.97	7.23

Alkermes has a net margin of 9.78% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 9.26% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Abeona Therapeutics	N/A	-53.98%	-38.52%

In the previous week, Abeona Therapeutics had 5 more articles in the media than Alkermes. MarketBeat recorded 15 mentions for Abeona Therapeutics and 10 mentions for Alkermes. Alkermes' average media sentiment score of 0.80 beat Abeona Therapeutics' score of 0.33 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alkermes beats Abeona Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Alkermes compare to Medpace?

Alkermes (NASDAQ:ALKS) and Medpace (NASDAQ:MEDP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Medpace has higher revenue and earnings than Alkermes. Medpace is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.86	$241.66M	$0.90	57.63
Medpace	$2.53B	5.98	$451.12M	$15.91	33.32

Alkermes has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

95.2% of Alkermes shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 20.5% of Medpace shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Medpace had 4 more articles in the media than Alkermes. MarketBeat recorded 14 mentions for Medpace and 10 mentions for Alkermes. Alkermes' average media sentiment score of 0.80 beat Medpace's score of 0.77 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes currently has a consensus target price of $51.25, indicating a potential downside of 1.20%. Medpace has a consensus target price of $469.50, indicating a potential downside of 11.45%. Given Alkermes' stronger consensus rating and higher probable upside, equities analysts plainly believe Alkermes is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Medpace	1 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.07

Medpace has a net margin of 17.19% compared to Alkermes' net margin of 9.78%. Medpace's return on equity of 120.89% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Medpace	17.19%	120.89%	24.79%

Summary

Medpace beats Alkermes on 10 of the 17 factors compared between the two stocks.

How does Alkermes compare to Omnicell?

Omnicell (NASDAQ:OMCL) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Omnicell has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Omnicell presently has a consensus target price of $59.86, indicating a potential upside of 28.23%. Alkermes has a consensus target price of $51.25, indicating a potential downside of 1.20%. Given Omnicell's stronger consensus rating and higher probable upside, equities analysts plainly believe Omnicell is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 4.6% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Alkermes had 2 more articles in the media than Omnicell. MarketBeat recorded 10 mentions for Alkermes and 8 mentions for Omnicell. Alkermes' average media sentiment score of 0.80 beat Omnicell's score of 0.58 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has higher revenue and earnings than Omnicell. Alkermes is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.79	$2.05M	$0.44	106.09
Alkermes	$1.48B	5.86	$241.66M	$0.90	57.63

Alkermes has a net margin of 9.78% compared to Omnicell's net margin of 1.67%. Alkermes' return on equity of 9.26% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.67%	4.00%	2.46%
Alkermes	9.78%	9.26%	5.66%

Summary

Alkermes beats Omnicell on 12 of the 17 factors compared between the two stocks.

How does Alkermes compare to AMN Healthcare Services?

Alkermes (NASDAQ:ALKS) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Alkermes currently has a consensus target price of $51.25, indicating a potential downside of 1.20%. AMN Healthcare Services has a consensus target price of $27.00, indicating a potential downside of 20.52%. Given Alkermes' stronger consensus rating and higher possible upside, equities analysts plainly believe Alkermes is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Alkermes has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

95.2% of Alkermes shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, AMN Healthcare Services had 9 more articles in the media than Alkermes. MarketBeat recorded 19 mentions for AMN Healthcare Services and 10 mentions for Alkermes. Alkermes' average media sentiment score of 0.80 beat AMN Healthcare Services' score of 0.38 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Alkermes has a net margin of 9.78% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
AMN Healthcare Services	-0.95%	18.01%	5.19%

Alkermes has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.86	$241.66M	$0.90	57.63
AMN Healthcare Services	$2.73B	0.48	-$95.70M	-$0.87	N/A

Summary

Alkermes beats AMN Healthcare Services on 12 of the 17 factors compared between the two stocks.

How does Alkermes compare to Biogen?

Biogen (NASDAQ:BIIB) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Biogen currently has a consensus price target of $220.04, indicating a potential upside of 5.27%. Alkermes has a consensus price target of $51.25, indicating a potential downside of 1.20%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	2 Sell rating(s)	11 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.55
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

87.9% of Biogen shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Biogen has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

In the previous week, Biogen had 23 more articles in the media than Alkermes. MarketBeat recorded 33 mentions for Biogen and 10 mentions for Alkermes. Biogen's average media sentiment score of 0.93 beat Alkermes' score of 0.80 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	18 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a net margin of 13.81% compared to Alkermes' net margin of 9.78%. Biogen's return on equity of 12.83% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	13.81%	12.83%	8.01%
Alkermes	9.78%	9.26%	5.66%

Biogen has higher revenue and earnings than Alkermes. Biogen is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.12	$1.29B	$9.32	22.43
Alkermes	$1.48B	5.86	$241.66M	$0.90	57.63

Summary

Biogen beats Alkermes on 10 of the 16 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALKS vs. The Competition

Export

Metric	Alkermes	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.66B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	57.63	20.85	27.11	24.26
Price / Sales	5.86	314.01	589.14	117.88
Price / Cash	31.02	61.98	29.22	49.36
Price / Book	4.71	8.49	10.75	6.29
Net Income	$241.66M	$23.83M	$3.58B	$330.66M
7 Day Performance	-6.07%	-3.56%	-2.10%	-1.35%
1 Month Performance	17.14%	6.31%	3.29%	-0.64%
1 Year Performance	74.71%	48.30%	26.32%	19.08%

Alkermes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALKS Alkermes	1.7424 of 5 stars	$51.87 -0.1%	$51.25 -1.2%	+71.3%	$8.66B	$1.48B	57.63	2,050	Analyst Forecast
ABEO Abeona Therapeutics	3.4325 of 5 stars	$6.31 -1.4%	$19.00 +201.1%	+22.1%	$364.77M	$5.82M	6.51	90
MEDP Medpace	1.9779 of 5 stars	$565.09 +1.3%	$467.08 -17.3%	+63.9%	$15.92B	$2.53B	35.52	6,200	Analyst Forecast
OMCL Omnicell	3.6438 of 5 stars	$45.24 +5.1%	$59.86 +32.3%	+62.7%	$1.96B	$1.18B	102.82	3,580	News Coverage
AMN AMN Healthcare Services	1.7713 of 5 stars	$35.84 +3.1%	$27.00 -24.7%	+60.5%	$1.35B	$2.73B	N/A	2,664	News Coverage Positive News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALKS) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alkermes (ALKS) Competitors

ALKS vs. ABEO, MEDP, OMCL, AMN, and BIIB

How does Alkermes compare to Abeona Therapeutics?

Summary

How does Alkermes compare to Medpace?

Summary

How does Alkermes compare to Omnicell?

Summary

How does Alkermes compare to AMN Healthcare Services?

Summary

How does Alkermes compare to Biogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS vs. The Competition

Alkermes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alkermes (ALKS) Competitors

ALKS vs. ABEO, MEDP, OMCL, AMN, and BIIB

How does Alkermes compare to Abeona Therapeutics?

Do analysts recommend ALKS or ABEO?

Which has more volatility & risk, ALKS or ABEO?

Do institutionals and insiders hold more shares of ALKS or ABEO?

Which has better earnings and valuation, ALKS or ABEO?

Is ALKS or ABEO more profitable?

Does the media prefer ALKS or ABEO?

Summary

How does Alkermes compare to Medpace?

Which has higher valuation and earnings, ALKS or MEDP?

Which has more risk and volatility, ALKS or MEDP?

Do institutionals & insiders believe in ALKS or MEDP?

Does the media refer more to ALKS or MEDP?

Do analysts prefer ALKS or MEDP?

Is ALKS or MEDP more profitable?

Summary

How does Alkermes compare to Omnicell?

Which has more volatility & risk, OMCL or ALKS?

Do analysts recommend OMCL or ALKS?

Do institutionals and insiders have more ownership in OMCL or ALKS?

Does the media favor OMCL or ALKS?

Which has preferable earnings and valuation, OMCL or ALKS?

Is OMCL or ALKS more profitable?

Summary

How does Alkermes compare to AMN Healthcare Services?

Do analysts prefer ALKS or AMN?

Which has more risk & volatility, ALKS or AMN?

Do insiders and institutionals hold more shares of ALKS or AMN?

Does the media refer more to ALKS or AMN?

Is ALKS or AMN more profitable?

Which has higher valuation and earnings, ALKS or AMN?

Summary

How does Alkermes compare to Biogen?

Do analysts recommend BIIB or ALKS?

Do institutionals & insiders believe in BIIB or ALKS?

Which has more risk and volatility, BIIB or ALKS?

Does the media prefer BIIB or ALKS?

Is BIIB or ALKS more profitable?

Which has higher earnings & valuation, BIIB or ALKS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS vs. The Competition

Alkermes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools